MedTrace Logo

Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer

NCT02009605 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-03-05

No results posted yet for this study

Summary

This study is designed to evaluate the efficacy of icotinib at routine dose in previously treated non/light-smoking patients with advanced squamous cell lung cancer.

Conditions

  • Squamous Cell Carcinoma of Lung

Interventions

DRUG

Icotinib

125mg, oral administration, three times per day.

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Zhao Qiong, Dr. · Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-01-31
Completion
2016-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02009605 on ClinicalTrials.gov